Drug Discovery & Development |
FDA Investigating Heart Failure Risk Linked To Onglyza
Forbes ureThe FDA said today that it was conducting an investigation of a possible increased risk for heart failure associated with the diabetes drug saxagliptin. Saxagliptin is marketed by AstraZeneca AstraZeneca as Onglyza and Kombiglyze XR. (AstraZeneca … FDA to Investigate Diabetes Drug Saxagliptin for Possible Heart Failure RiskU.S. News & World Report FDA to probe saxagliptin’s heart failure riskFamily Practice News Digital Network FDA Investigating Heart Failure Risks with SaxagliptinDrug Discovery & Development Healio all 27 news articles » |
Mizoram likely to lift liquor ban – MorungExpress
Mizoram likely to lift liquor banMorungExpressLalhrekima, quoting the Aizawl Civil Hospital records, said 282 people were admitted with liver diseases between 1992 and 1996 while 520 cases of liver disease due to spurious liquor consumption were report…
Study: Resilience in parents of children undergoing stem cell transplant – Science Codex
|
Study: Resilience in parents of children undergoing stem cell transplant
Science Codex A child’s illness can challenge a parent’s wellbeing. However, a study recently published in the journal Biology of Blood and Marrow Transplantation shows that in the case of a child’s stem cell transplant, parents feel increased distress at the time … Children’s Medical Center to Host 23rd Annual ‘Be The Match’ Donor Registry …The Herald | HeraldOnline.com (press release) |
Avaxia Biologics Awarded Patent with Broad Coverage over Oral Anti-TNF … – Business Wire (press release)
Avaxia Biologics Awarded Patent with Broad Coverage over Oral Anti-TNF …Business Wire (press release)The patent covers milk-derived anti-TNF antibodies that are orally administered within a broad dose range for the treatment of inflammatory bowel dis…
Gilead seeks approval for first-ever oral Hepatitis C drug – San Francisco Chronicle (blog)
Gilead seeks approval for first-ever oral Hepatitis C drugSan Francisco Chronicle (blog)Gilead is also taking heat internationally for its tentative plans to bring Sovaldi to India and other developing countries at a fraction of the U.S. price, about $…
Study: Resilience in Parents of Children Undergoing Stem Cell Transplant – Newswise (press release)
|
Study: Resilience in Parents of Children Undergoing Stem Cell Transplant
Newswise (press release) Newswise — A child’s illness can challenge a parent’s wellbeing. However, a study recently published in the journal Biology of Blood and Marrow Transplantation shows that in the case of a child’s stem cell transplant, parents feel increased distress … |
What made Gilead Sciences choose Mylan as India partner – Hindu Business Line
Hindu Business Line |
What made Gilead Sciences choose Mylan as India partner
Hindu Business Line A big difference between the US and India is that the US spends money on treating effects of hepatitis C. For example, in terms of liver transplants, liver cancer — there is a huge burden of hepatitis C currently picked up by the health system. The … |
Gilead seeks approval for Hepatitis C drug that's innovative — and expensive – San Francisco Chronicle (blog)
|
Gilead seeks approval for Hepatitis C drug that’s innovative — and expensive
San Francisco Chronicle (blog) Gilead is also taking heat internationally for its plans to bring Sovaldi to India and other developing countries at a fraction of the U.S. price, about $2,500 for six months of treatment, according to an interview with an Indian pharmaceutical … |
The Weekend Warrior's 1st Berlinale Experience – Part 1 – ComingSoon.net
ComingSoon.net |
The Weekend Warrior’s 1st Berlinale Experience – Part 1
ComingSoon.net At that point, I was still in mid-recovery from my stem cell transplant, but it was just one of those opportunities that was really hard to say “no” to. So I didn’t. I knew that the trip was a few months off and I mentioned it to my doctor and then … |
FDA to review heart failure risk associated with saxagliptin – Healio
FDA to review heart failure risk associated with saxagliptinHealioThe FDA requested additional clinical trial data for saxagliptin due to potential heart failure risks, according to an announcement released today. Concerns arose after data cited an inc…